The Frequency of PD-L1 Marker Expression in ER Positive, PR Positive, HER2 Negative Invasive Breast Carcinomas, and Its Correlation with Clinicopathological Factors Affecting Prognosis
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: The aim of this study was to investigate the expression of the PD-L1 marker in ER-positive, PR-positive, and HER2-negative breast carcinoma and examine its correlation with clinicopathological factors that affect prognosis in these patients. Materials and Methods: This cross-sectional descriptive–analytical study was conducted on paraffin-embedded tissue blocks from 50 invasive breast carcinoma patients. PD-L1 immunohistochemical staining was performed, and samples were examined to assess the membranous staining of tumor cells with the PD-L1 marker. ER, PR, and HER2 results were obtained from the pathology reports. The tumor proliferative index was divided into two groups: low proliferative index (<14%) and high proliferative index (= or >14%), based on the percentage of tumor cell nuclei with positive staining. Results: PD-L1 expression was negative in 44 (88%) and positive in 6 samples (12%). There was no significant difference in the mean age, tumor grade, and tumor proliferative index between the two groups ( P value > 0.05). All positive PD-L1 samples belonged to the IDC tumor subtype with a mean tumor size of 6.33 ± 6.41 cm. In the negative PD-L1 group, 88.6% were IDC, 4.5% were ILC, and 6.8% were mixed tumor subtypes, with a mean tumor size of 2.79 ± 1.54 cm. Tumor subtype, tumor size, and axillary lymph node status showed no significant difference between the two groups ( P value > 0.05). Conclusion: According to the results of this study, there is no relationship between the PD-L1 expression and well-known clinicopathological prognostic factors in ER-positive, PR-positive, and HER2-negative invasive breast carcinomas.
Source: Advanced Biomedical Research
Institution: Isfahan University of Medical Sciences
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $300
OpenAlex ID: W7117530207